Chaperone Therapy for Neuronopathic Lysosomal Diseases: Competitive Inhibitors as Chemical Chaperones for Enhancement of Mutant Enzyme Activities
Perspectives in Medicinal Chemistry · 2009
DOI: 10.4137/pmc.s2332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Perspectives in Medicinal Chemistry, 2009. Verfasst von Yoshiyuki Suzuki und 2 weiteren Autor:innen. Beteiligte Einrichtung: International University of Health and Welfare Graduate School, Kita Kanemaru, Otawara, 324-8501 Japan. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Chaperone therapy is a newly developed molecular approach to lysosomal diseases, a group of human genetic diseases causing severe brain damage. We found two valienamine derivatives, N-octyl-4-epi-β-valienamine (NOEV) and N-octyl-β-valienamine (NOV), as promising therapeutic agents for human β-galactosidase deficiency disorders (mainly G M1 -gangliosidosis) and β-glucosidase deficiency disorders (Gaucher disease), respectively. We briefly reviewed the historical background of research in carbasugar glycosidase inhibitors. Originally NOEV and NOV had been discovered as competitive inhibitors, and then their paradoxical bioactivities as chaperones were confirmed in cultured fibroblasts from patients with these disorders. Subsequently G M1 -gangliosidosis model mice were developed and useful for experimental studies. Orally administered NOEV entered the brain through the blood-brain barrier, enhanced β-galactosidase activity, reduced substrate storage, and improved neurological deterioration clinically. Furthermore, we executed computational analysis for prediction of molecular interactions between β-galactosidase and NOEV. Some preliminary results of computational analysis of molecular interaction mechanism are presented in this article. NOV also showed the chaperone effect toward several β-glucosidase gene mutations in Gaucher disease. We hope chaperone therapy will become available for some patients with G M1 -gangliosidosis, Gaucher disease, and potentially other lysosomal storage diseases with central nervous system involvement.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- International University of Health and Welfare Graduate School, Kita Kanemaru, Otawara, 324-8501 Japan.
Zitieren
APA
Suzuki, Y., Ogawa, S., & Sakakibara, Y. (2009). Chaperone Therapy for Neuronopathic Lysosomal Diseases: Competitive Inhibitors as Chemical Chaperones for Enhancement of Mutant Enzyme Activities. Perspectives in Medicinal Chemistry. https://doi.org/10.4137/pmc.s2332
Vancouver
Suzuki Y, Ogawa S, Sakakibara Y. Chaperone Therapy for Neuronopathic Lysosomal Diseases: Competitive Inhibitors as Chemical Chaperones for Enhancement of Mutant Enzyme Activities. Perspectives in Medicinal Chemistry. 2009. doi:10.4137/pmc.s2332
BibTeX
@article{Suzuki2009,
author = {Suzuki, Yoshiyuki and Ogawa, Seiichiro and Sakakibara, Yasubumi},
title = {Chaperone Therapy for Neuronopathic Lysosomal Diseases: Competitive Inhibitors as Chemical Chaperones for Enhancement of Mutant Enzyme Activities},
journal = {Perspectives in Medicinal Chemistry},
year = {2009},
doi = {10.4137/pmc.s2332}
}
EUVIMED